Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

Launched by INCYTE CORPORATION · Jun 16, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at patients who have recently received an allogeneic stem cell transplant (a procedure where stem cells from a donor are used to replace damaged cells in a patient) and are at risk for developing chronic graft-versus-host disease (cGVHD). cGVHD is a condition where the donated cells attack the patient's body, which can lead to various health issues. The study aims to gather information about these patients to better understand how to manage and prevent cGVHD.

To participate in this study, individuals must be at least 18 years old and have had their stem cell transplant between 90 and 180 days prior to joining the trial. There are no specific exclusions, so many patients may be eligible. Participants will be asked to complete questionnaires about their health, either on their own or with some help. This study is currently recruiting, and your involvement could contribute to important research that may help other patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years inclusive at the time of signing the ICF
• • Allogeneic SCT 90 to 180 days prior to enrollment
• • Able to comprehend and willing to provide informed consent
• • Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
• Exclusion Criteria:
• • There are no exclusion criteria for this study